Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2504 | Nasal Swab Wiki | 0.35 |
| drug3963 | Tests Wiki | 0.35 |
| drug1051 | Convalescent Plasma 2 Units Wiki | 0.35 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4637 | oropharyngeal swabs Wiki | 0.35 |
| drug3195 | Questionnaire by phone call Wiki | 0.35 |
| drug3200 | Questionnaire with precaution information Wiki | 0.35 |
| drug3270 | Rapid detection test Wiki | 0.35 |
| drug2720 | Optional questionnaire completion Wiki | 0.35 |
| drug2719 | Optional blood completion Wiki | 0.35 |
| drug4159 | Urine sample Wiki | 0.35 |
| drug1537 | Fingerstick Wiki | 0.35 |
| drug3041 | Povidone-Iodine (PVP-I) Wiki | 0.35 |
| drug1050 | Convalescent Plasma 1 Unit Wiki | 0.35 |
| drug3517 | Saliva sample Wiki | 0.35 |
| drug1382 | End tidal breath sample Wiki | 0.35 |
| drug4222 | Video based exercise Wiki | 0.35 |
| drug3196 | Questionnaire collection Wiki | 0.35 |
| drug4481 | exercise brochure Wiki | 0.35 |
| drug1160 | Data collection Wiki | 0.35 |
| drug1455 | Experimental: Questionnaire without precaution information Wiki | 0.35 |
| drug3519 | Saliva specimen Wiki | 0.35 |
| drug3691 | Sputum sample Wiki | 0.35 |
| drug3785 | Stool collection Wiki | 0.35 |
| drug4006 | Throat swab Wiki | 0.25 |
| drug637 | Breath Biopsy face masks with removable filters and fitted PVA strip Wiki | 0.25 |
| drug3600 | Serum testing Wiki | 0.25 |
| drug3938 | Telerehabilitation Wiki | 0.18 |
| drug1776 | Hydroxychloroquine (HCQ) Wiki | 0.16 |
| drug605 | Blood sample Wiki | 0.11 |
| drug3728 | Standard of Care Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012859 | Sjogren's Syndrome NIH | 0.18 |
| D015535 | Arthritis, Psoriatic NIH | 0.18 |
| D001327 | Autoimmune Diseases NIH | 0.16 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011565 | Psoriasis NIH | 0.14 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.14 |
| D012327 | RNA Virus Infections NIH | 0.14 |
| D001168 | Arthritis NIH | 0.08 |
| D012120 | Respiration Disorders NIH | 0.08 |
| D003141 | Communicable Diseases NIH | 0.08 |
| D012140 | Respiratory Tract Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
| D014777 | Virus Diseases NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002960 | Autoimmunity HPO | 0.16 |
| HP:0003765 | Psoriasiform dermatitis HPO | 0.14 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.14 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001369 | Arthritis HPO | 0.08 |
Navigate: Correlations HPO
There are 8 clinical trials
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD (AECOPD) episodes.
Description: An Acute Exacerbation in a COPD patient is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum production and beyond normal day to day variations, that is acute in onset and may warrant a change in regular medication in a patient with underlying COPD The Means and Confidence Intervals (CI) were estimated using the Negative Binomial model taking into account time to follow up. Estimated exacerbations were presented as mean number of exacerbations per (/) subject/ year.
Measure: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) Time: During year 1Description: Bacterial pathogens assessed were: Haemophilus influenzae (Hi), Moraxella catarrhalis (Mcat), Steptococcus pneumoniae (Sp), Staphylococcus Aureus (Sta), Pseudomonas aeruginosa (Psa), any or other. For each bacteria, the means and CIs were estimated from Negative Binomial model taking into account the follow up time.Estimated exacerbations were presented as mean number of exacerbations/ subject/ year.
Measure: Mean Estimated Number of AECOPD With Sputum Containing Bacterial Pathogens Time: During Year 1Description: Bacterial pathogens assessed, by culture, were: Haemophilus influenzae (Hi), Moraxella catarrhalis (Mcat), Streptococcus pneumoniae (Sp), Staphylococcus aureus (Sta), Pseudomonas aeruginosa (Psa), any bacteria or other bacteria. Overall exacerbation rate is the average number of exacerbations for each subject during their time in the study.
Measure: Overall AECOPD Exacerbation Rate for Any and Specific Bacterial Pathogens in Sputum Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for any bacteria and Hi.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Any Bacteria and Hi Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for Mcat and Sp.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Mcat and Sp Time: During Year 1Description: Sputum samples were tested by bacterial species (any bacteria, Hi, Mcat, Sp, Sta, Psa and other bacteria), or overall and were obtained from culture at each visit (enrollment, any stable visit, any exacerbation visit, any mild exacerbation visit, any moderate exacerbation visit, any severe exacerbation visit). This endpoint presents results for Sta, Psa and other bacteria.
Measure: Number of Sputum Samples Positive for Specific Pathogens - Sta, Psa and Other Bacteria Time: During Year 1Description: The number of days between 2 consecutive exacerbations, as estimated by the investigator, was calculated only whenever the first exacerbation had an end date.
Measure: Mean Number of Days Between 2 Consecutive AECOPDs Time: During Year 1Description: The exacerbations of chronic pulmonary disease tool version 1.0 (EXACT) is a validated self-administered instrument that evaluates the effects of pharmacologic treatment on acute exacerbations of COPD. Analyses of exacerbations in relation to morning or evening EXACT-PRO e-diaries were presented as follows: descriptive statistics on the EXACT daily scores tabulated at enrolment, at any stable and at any, mild, moderate or severe exacerbation visit. EXACT-PRO contains 14 questions with scores ranging from 0 to 4, where 0= best outcome while 4= worse outcome.
Measure: Change From Baseline EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The COPD assessment test (CAT) is a validated self-administered instrument designed to provide a simple and reliable measure of health status in COPD patients. Its properties have been shown to be similar to the St George's respiratory questionnaire (SGRQ). The CAT comprises 8 items and has a scoring range of 0-40, 0= most positive answer and 40= most negative answer. In this study, the subjects were to complete the CAT questionnaire every 3 months.
Measure: Change From Baseline COPD Assessment Test (CAT) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The NEADL assessed (quarterly in the present study) the ease or difficulty in performing extended activities of daily living. The NEADL scale contains 22 items, each measured on a 4-point Likert scale. There are four dimensions: mobility (6 items); kitchen (5 items); domestic (5 items); leisure (6 items). These are summed producing a total score reflecting general functioning. Each of the 22 individual items had 2 possible scores (0 or 1). Therefore, the range of the NEADL score was 0 to 22. Lower scores indicate greater levels of disability while higher scores indicate greater independence.
Measure: Change From Baseline COPD Nottingham Extended Activities of Daily Living Scale (NEADL) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: The EQ-5D is an established measure of generic health outcome that provides a simple descriptive profile and a single index value that can be used in clinical and economic evaluation of healthcare and in population surveys. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 100 (best health state). The negative numbers presented represent a decrease from baseline values and a worsening of health.
Measure: Change From Baseline COPD EQ-5D Index and Visual Analogue Scale (VAS) Scores at Enrollment and Any AECOPD Visit Time: During Year 1Description: AECOPD health care type included: general practitioners (other than the study doctor), pneumologists, other specialists, hospital emergency department, home care nurses, pulmonary rehabilitation programs and/or nutrition advices.
Measure: Number of Subjects Receiving Various Health Care Types During AECOPD Time: During Year 1Description: Serious adverse events (SAEs) include medical occur-rences that result in death, are life threatening, require hospitali-zation or prolongation of hospitalization or result in disabil-ity/incapacity.
Measure: Number of Subjects With Serious Adverse Events (SAEs) Possibly Related/Linked to Withdrawal Time: During Year 1Description: Bacterial pathogens assessed, by PCR assay were: Hi, Mcat, Sp, Sta, Psa, Streptococcus pyogenes (Spyo) and any bacteria.
Measure: AECOPD Rate With Overall and Specific Bacterial Pathogens in Sputum , by Polymerase Chain Reaction (PCR) Assay Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus.
Measure: AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Mild exacerbations were defined as worsening symptoms of COPD that were self-managed by the patient.
Measure: Mild-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Moderate exacerbations were defined as worsening symptoms of COPD that required treatment with oral corticosteroids and/or antibiotics.
Measure: Moderate-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: Viral pathogens assessed were: respiratory syncytial virus (RSV), parainfluenza virus (PIV), entero rhinovirus (ENV), human metapneumovirus (HMP), influenza virus (INV), adenovirus (ADV), coronavirus (CRV), human bocavirus (HBoV) and any virus. Severe exacerbations were defined as worsening symptoms of COPD that required treatment with in-patient hospitalisation or home care intervention.
Measure: Severe-AECOPD Rate With Overall and Specific Viral Pathogens in Sputum Time: During Year 1Description: An Acute Exacerbation in a COPD patient is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum production and beyond normal day to day variations, that is acute in onset and may warrant a change in regular medication in a patient with underlying COPD. AECOPD severity was assessed as: any, mild, moderate and severe. Any = any COPD symptom regardless of severity. Mild = Worsening symptoms of COPD that are self-managed by the patient. Moderate = Worsening symptoms of COPD that require treatment with oral corticosteroids and/or antibiotics. Severe = Worsening symptoms of COPD that require treatment with in-patient hospitalisation or home care intervention.
Measure: AECOPD Rate With Overall and Specific Bacterial Pathogens in Sputum by Severity Time: During Year 1This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
According to epidemiological models, the seroprevalence of SARS-CoV-2 infection in Île-de-France as of 11 May was between 10 and 15%. Preliminary data on the number of professionals evicted from nurseries on suspicion of COVID-19 (on clinical grounds) seem to be of the same order of magnitude, but need to be confirmed by a biological technique. Children would be susceptible to infection but often asymptomatic.
Description: Proportion of children with a positive rapid serological test (presence of anti-SARS-CoV2 antibodies (IgM or IgG)).
Measure: Assess the serological status/rate of past infections in the children of priority staff in the nursery during the containment period Time: Day of intervention (1 day)The primary aim of this study is to investigate the performance of Breath Biopsy RD for the detection of SARS-CoV-2 in both a clinical and at home setting.
Description: The purpose of this stage is to confirm the optimal extraction protocol to detect the presence of SARS-CoV-2 from the aerosols captured in the Breath Biopsy RD device. Up to two Breath Biopsy RD sample will be collected alongside a nasopharyngeal. The swab obtained during this stage is to be analysed in parallel to the extracted breath aerosols in the lab of the lab and will be used as a positive control.
Measure: Positive control for technical validation Time: 1 yearDescription: The aim is to assess the test performance of the Breath Biopsy RD devices in a real live clinical setting. Subjects with a high clinical suspicion of nCOVID-19 based on clinical triage will be requested to participate. A single Breath Biopsy RD collector will be collected in parallel with the standard diagnostic work-up consisting of a CT-scan and a nasopharyngeal swab.
Measure: Evaluation of test performance Time: 1 yearDescription: The aim of the final outcome is to evaluate the performance and acceptability of using the Breath Biopsy RD as an at home test for identification of the presence of SARS-CoV-2. The OLVG phone application used for triage of the presence of nCOVID-19 will be used to identify subjects at the highest risk of having nCOVID-19. These subjects will be sent a Breath Biopsy RD collector and oropharyngeal swab for at home testing. Any subject who has a positive Breath Biopsy test for SARS-CoV-2 will be contacted and advised to receive a nasopharyngeal test for assessment of viral presence. Both tests will be self-administered to mimic an at home use scenario. The performance of both tests will be confirmed from the perspective of 1. Adherence 2. Subject comfort 3. Number of SARS-CoV-2 positive cases.
Measure: Evaluation of at home test Time: 1 yearPerformance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
Description: Evaluation of performance of the device versus a reference method using standard qualitative comparison techniques (Percent Agreement)
Measure: Performance Evaluation Time: 4 monthsRecent studies have shown that some individuals may be asymptomatic but continue to shed the COVID-19 virus. These individuals may represent a population that can unknowingly transmit the virus. Healthcare workers (HCW) may acquire COVID-19 from the community or from possibly infected patients. It is important to gather data with respect to this to further understand the prevalence of asymptomatic carriage in individuals who work in research facilities, offices and clinical areas of hospitals and research facilities/institutes since this has important implications for infection control, as well as staff and patient safety. The purpose of this study is to test whether a proportion of these individuals may be asymptomatic shedders of the COVID-19 virus.
The investigators hypothesize that detection of SARS-CoV2 on saliva samples will increase the performance of the screening program compared to the reference strategy (RT-PCR on a nasopharyngeal swab).
Description: RT-PCR on nasopharyngeal is considered as gold standard
Measure: Positivity of RT-PCR on nasopharyngeal swab for the SARS-CoV-2 virus Time: At diagnosisDescription: Number of samples tested in a day for each test
Measure: Practicability to samples Time: At diagnosisDescription: Quantity of premises required for each test
Measure: Practicability to premises Time: At diagnosisDescription: Feasibly Reading and interpretation For each test
Measure: Practicability to interpretation Time: At diagnosisDescription: Render times for each test
Measure: Practicability to render time Time: At diagnosisDescription: Research of IgG by ELISA and RDT
Measure: IgG Antibody detection in saliva Time: At diagnosisDescription: Research of IgM by ELISA and RDT
Measure: IgM Antibody detection in saliva Time: At diagnosisDescription: Research of IgA by ELISA and RDT
Measure: IgA Antibody detection in saliva Time: At diagnosisDescription: Evaluation by questionnaire of the patient tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions are about pain, discomfort, speed of performance)
Measure: Patient tolerance of the salivary self-sampling Time: At diagnosisDescription: Evaluation by questionnaire of the operator tolerance of the salivary self-sampling compared to the nasopharyngeal swab (questions is about pain, discomfort, speed of performance)
Measure: Operator tolerance of the salivary self-sampling Time: At diagnosisDescription: Including sampling, transport, technique (consumables, reagents, machine), human resources
Measure: Cost of each approach Time: At diagnosisThe main objectives of this study are 1. to establish the prevalence of SARS-CoV-2 in schools and kindergartens in the State of Mecklenburg-Vorpommern in autumn and winter 2020/2021 2. to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in teachers and childcare educators over time
Description: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 5 monthsDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: At study inclusionDescription: Percentage of Anti-SARS-COV2 S protein IgA and IgA ELISA positive participants (educational staff)
Measure: Seroprevalence of SARS-CoV-2 antibodies Time: 5 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: At study inclusionDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 1 monthDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 2 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 3 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 4 monthsDescription: As assessed by a monthly questionnaire
Measure: SARS-CoV-2 risk factors, perceived risk of infection, and impact of the pandemic on quality of life Time: 5 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: At study inclusionDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 1 monthDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 2 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 3 monthsDescription: Percentage of SARS-CoV-2 PCR positive participants (children and educational staff)
Measure: Share of participants with SARS-CoV-2 detectable in PCR Time: 4 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports